Alligator Bioscience AB (publ)

OM:ATORX Stock Report

Market Cap: SEK 199.7m

Alligator Bioscience Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Søren Bregenholt

Chief executive officer

SEK 5.2m

Total compensation

CEO salary percentage68.9%
CEO tenure3.5yrs
CEO ownershipn/a
Management average tenure2.9yrs
Board average tenure3yrs

Recent management updates

Recent updates

Will Alligator Bioscience (STO:ATORX) Spend Its Cash Wisely?

Dec 01
Will Alligator Bioscience (STO:ATORX) Spend Its Cash Wisely?

We're Keeping An Eye On Alligator Bioscience's (STO:ATORX) Cash Burn Rate

Dec 21
We're Keeping An Eye On Alligator Bioscience's (STO:ATORX) Cash Burn Rate

Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?

Jul 30
Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?

Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?

Jan 06
Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?

Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation

Aug 18
Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation

CEO Compensation Analysis

How has Søren Bregenholt's remuneration changed compared to Alligator Bioscience's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-SEK 248m

Jun 30 2024n/an/a

-SEK 234m

Mar 31 2024n/an/a

-SEK 249m

Dec 31 2023SEK 5mSEK 4m

-SEK 249m

Sep 30 2023n/an/a

-SEK 232m

Jun 30 2023n/an/a

-SEK 231m

Mar 31 2023n/an/a

-SEK 213m

Dec 31 2022SEK 4mSEK 3m

-SEK 193m

Sep 30 2022n/an/a

-SEK 177m

Jun 30 2022n/an/a

-SEK 163m

Mar 31 2022n/an/a

-SEK 152m

Dec 31 2021SEK 4mSEK 2m

-SEK 142m

Compensation vs Market: Søren's total compensation ($USD470.67K) is above average for companies of similar size in the Swedish market ($USD230.61K).

Compensation vs Earnings: Søren's compensation has increased whilst the company is unprofitable.

CEO

Søren Bregenholt (53 yo)

3.5yrs

Tenure

SEK 5,201,000

Compensation

Mr. Søren Bregenholt, Ph D serves as the Chief Executive Officer at Alligator Bioscience AB (publ) since June 01, 2021. He served as the Chief Operating Officer of Symphogen A/S.Mr. Bregenholt served as S...

Leadership Team

NamePositionTenureCompensationOwnership
Søren Bregenholt
Chief Executive Officer3.5yrsSEK 5.20mno data
Johan Gileus
Chief Financial Officerless than a yearno datano data
Laura von Schantz
Chief Technology Officer2.9yrsno datano data
Peter Ellmark
Chief Scientific Officer3.9yrsno datano data
Greta Eklund
Investor Relations & Communications Managerno datano datano data
Sumeet Ambarkhane
Chief Medical Officer2.8yrsno datano data

2.9yrs

Average Tenure

53yo

Average Age

Experienced Management: ATORX's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Staffan Encrantz
Independent Director2.6yrsSEK 300.00kno data
Anders Ekblom
Independent Chairman of the Board7.6yrsSEK 700.00k0.015%
SEK 30.7k
Hans-Peter Ostler
Independent Vice Chairman of the Board3.5yrsSEK 525.00kno data
Denise Goode
Independent Director2.6yrsSEK 350.00kno data
Eva Saers
Independent Director3.5yrsSEK 350.00kno data
Karin Nordbladh
Employee Representative Director1.9yrsno datano data

3.0yrs

Average Tenure

66yo

Average Age

Experienced Board: ATORX's board of directors are considered experienced (3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 14:09
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alligator Bioscience AB (publ) is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ingrid GafanhãoKempen & Co. NV
Carl RamaniusRedeye